VMD Medicines Update - November 2020 | British Equine Veterinary Association
We have updated our Privacy Policy. You can find out more here.
BEVA Logo

VMD Medicines Update - November 2020

News Medicines
04 Jan 2021 BEVA


New MAs and changes made and published to end of November 2020

The points below highlight changes in marketing authorisations (MAs) that may have a significant impact on veterinary surgeons’ prescribing decisions.

New marketing authorisations

New marketing authorisations relevant to veterinary surgeons in the UK that were issued or published in November are listed in Table 1.

Table 1 also indicates where a public assessment report should become available for a product. Where available, links to these reports are accessible by clicking on the relevant product on the VMD’s Product Information Database https://www.gov.uk/check-animal-medicine-licensed

The European Medicines Agency (EMA) publishes European Public Assessment Reports (EPARs) for every veterinary medicine which is authorised through a centralised procedure. Links to these reports are accessible here.

 

Marketing Authorisations issued/published in November 2020

Product name

Active substance

Authorisation Holder

Public Assessment Report to be made available from VMD?

 

Isoflurin 1000 mg/g inhalation vapour, liquid

 

For use in Cats, Chinchilla, Dogs, Ferrets, Gerbil, Guinea Pigs, Hamsters, Horses, Mice, Ornamental Birds, Rats, Reptiles

Isoflurane

Vetpharma Animal Health, S.L

No – RMS Netherlands

In prescribing these veterinary medicines, veterinary surgeons should be aware that changes to the Summary of Product Characteristics (SPC), labels and leaflets may, in certain cases, change how the medicines should be used. The timing of when such changes have to be taken into account will depend on the circumstances, but as a general rule unless a prescriber has been advised otherwise by the manufacturer or the VMD the labelling instructions on the pack from which the product is dispensed should be followed.

VMD contact for this article: Vivienne Saville; v.saville@vmd.gov.uk